A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.

Antimicrob Agents Chemother · 2020 · PMC7674035 · PMID 32958718

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

First, the sample size of this study was based on an earlier report of a nonrandomized study from China, which reported highly significant viral clearance rates in the first 5 days of therapy with favipiravir plus interferon alpha compared with lopinavir-ritonavir plus interferon alpha.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.